Mutual of America Capital Management LLC reduced its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 2.5% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 300,968 shares of the company's stock after selling 7,648 shares during the period. Johnson & Johnson comprises approximately 0.6% of Mutual of America Capital Management LLC's holdings, making the stock its 18th largest position. Mutual of America Capital Management LLC's holdings in Johnson & Johnson were worth $49,913,000 at the end of the most recent quarter.
Other hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its stake in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after buying an additional 6,332 shares during the last quarter. Hudson Value Partners LLC raised its stake in Johnson & Johnson by 2.5% during the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock valued at $5,648,000 after buying an additional 1,022 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in Johnson & Johnson during the 4th quarter valued at $133,267,000. Bernard Wealth Management Corp. bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at $36,000. Finally, Waddell & Associates LLC grew its position in shares of Johnson & Johnson by 10.1% during the 4th quarter. Waddell & Associates LLC now owns 6,786 shares of the company's stock valued at $981,000 after acquiring an additional 620 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on the stock. Morgan Stanley boosted their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Raymond James Financial cut their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research report on Monday, April 14th. Wall Street Zen downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Friday, July 18th. Leerink Partnrs downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Finally, Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Nine analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and an average target price of $174.50.
Get Our Latest Stock Report on JNJ
Johnson & Johnson Trading Up 1.1%
Shares of NYSE:JNJ traded up $1.87 during trading on Friday, reaching $173.40. The company's stock had a trading volume of 7,686,049 shares, compared to its average volume of 9,496,232. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $173.96. The firm's 50 day simple moving average is $159.26 and its two-hundred day simple moving average is $157.44. The stock has a market capitalization of $417.61 billion, a PE ratio of 18.55, a price-to-earnings-growth ratio of 2.18 and a beta of 0.41.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter last year, the firm earned $2.82 EPS. The firm's revenue for the quarter was up 5.8% compared to the same quarter last year. On average, research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is 55.61%.
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
See Also
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
